Romidepsin for peripheral T-cell lymphoma

Expert Review of Hematology

Volumn 6, Issue 4, 2013, Pages 351-359

  Khot, Amit ^a   Dickinson, Michael ^a,b   Prince, H Miles ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

depsipeptide; HDAC inhibitors; romidepsin; T cell lymphoma

Indexed keywords

ANTIBIOTICS, ANTINEOPLASTIC; CLINICAL TRIALS AS TOPIC; DEPSIPEPTIDES; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84894109459     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/17474086.2013.814833     Document Type: Article

References (58)

1. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117(19), 5019-5032 (2011).
2. Project IT-CL. International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes. J. Clin. Oncol. 26(25), 4124-4130 (2008).
3. Dearden CE, Johnson R, Pettengell R, Devereux S, Cwynarski K, Whittaker S et al. Guidelines for the management of mature T-cell and NK-cell neoplasms (excluding cutaneous T-cell lymphoma). Br. J. Haematol. 153(4), 451-485 (2011).
4. NCCN. Clinical Practice Guidelines in Oncology (2013).
5. Escalón MP, Liu NS, Yang Y et al. Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma. Cancer 103(10), 2091-2098 (2005).
6. Yamaguchi M, Kwong YL, Kim WS et al. Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J. Clin. Oncol. 29(33), 4410-4416 (2011).
7. Gascoyne RD, Aoun P, Wu D, et al. Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma. Blood 93(11), 3913-3921 (1999).
8. Armitage JO, Vose JM, Weisenburger DD. Towards understanding the peripheral T-cell lymphomas. Ann. Oncol. 15(10), 1447-1449 (2004).
9. Piekarz RL, Frye R, Turner M et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J. Clin. Oncol. 27(32), 5410-5417 (2009).
10. Whittaker SJ, Demierre MF, Kim EJ et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 28(29), 4485-4491 (2010).
11. Schmitz N, Trumper L, Ziepert M et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 116(18), 3418-3425 (2010).
12. Gressin R, Peoch M, Deconinck E et al. The VIP-ABVD regimen is not superior to the CHOP 21 for the treatment of non epidermotropic peripheral T cell lymphoma. Final Results of the 'LTP95' Protocol of the GOELAMS. ASH Annual Meeting Abstracts. 108(11), 2464 (2006).
13. Tilly H, Lepage E, Coiffier B et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 102(13), 4284-4289 (2003).
14. Reimer P, Rüdiger T, Geissinger E et al. Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study. J. Clin. Oncol. 27(1), 106-113 (2009).
15. d'Amore F, Relander T, Lauritzsen GF et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J. Clin. Oncol. 30(25), 3093-3099 (2012).
16. Yared J, Kimball A. The role of high dose chemotherapy and autologous stem-cell transplantation in peripheral T-cell lymphoma: a review of the literature and new perspectives. Cancer Treat. Rev. 39(1), 51-59 (2013).
17. Dodero A, Spina F, Narni F et al. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. Leukemia 26(3), 520-526 (2012).
18. Kanakry JA, Kasamon YL, Gocke CD et al. Outcomes of related donor hla-identical or hla-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol. Blood Marrow Transplant. 19(4), 602-606 (2013).
19. Spencer A, Reed K, Arthur C. Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim. Intern. Med J. 37(11), 760-706 (2007).
20. Enblad G, Hagberg H, Erlanson M et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood 103(8), 2920-2924 (2004).
21. O'Connor OA, Horwitz S, Hamlin P et al. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals mrked activity in T-cell malignancies. J. Clin. Oncol. 27(26), 4357-4364 (2009).
22. Zinzani PL, Musuraca G, Tani M et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J. Clin. Oncol. 25(27), 4293-4297 (2007).
23. Mercieca J, Matutes E, Dearden C, MacLennan K, Catovsky D. The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype. J. Clin. Oncol. 12(12), 2588-2593 (1994).
24. Zinzani PL, Alinari L, Tani M, Fina M, Pileri S, Baccarani M. Preliminary observations of a Phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma. Haematologica 90(5), 702-703 (2005).
25. Dang NH, Pro B, Hagemeister FB et al. Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma. Br. J. Haematol. 136(3), 439-447 (2007).
26. Foss F, Sjak-Shie N, Goy A, Jacobsen E, Advani R, Smith M et al. Denileukin diftitox (ONTAK) plus CHOP chemotherapy in patients with peripheral T-cell lymphomas (PTCL), the CONCEPT trial. ASH Annual Meeting Abstracts. 110(11), 3449 (2007).
27. Damaj G, Gressin R, Bouabdallah K et al. Results from a prospective, open-label, Phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J. Clin Oncol. 31(1), 104-110 (2013).
28. O'Connor OA, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B et al. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J. Clin Oncol. 29(9), 1182-1189 (2011).
29. Pro B, Advani R, Brice P et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a Phase II study. J. Clin Oncol. 30(18), 2190-2196 (2012).
30. Harrison SJ, Bishton M, Bates SE, Grant S, Piekarz RL, Johnstone RW et al. A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(R)). Epigenomics. 4(5), 571-589 (2012).
31. Gryder BE, Sodji QH, Oyelere AK. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed. Future Med Chem. 4(4), 505-524 (2012).
32. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Dis. 5(9), 769-784 (2006).
33. Dickinson M, Johnstone RW, Prince HM. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest. New Drugs. 28(Suppl. 1), S3-S20 (2010).
34. Piekarz RL, Bates SE. Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res. 15(12), 3918-3926 (2009).
35. Bereshchenko OR, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat. Genetics. 32(4), 606-613 (2002).
36. Finnin MS, Donigian JR, Cohen A et al. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401(6749), 188-193 (1999).
37. VanderMolen KM, McCulloch W, Pearce CJ, Oberlies NH. Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma. J. Antibiotics. 64(8), 525-531 (2011).
38. Xiao JJ, Byrd J, Marcucci G, Grever M, Chan KK. Identification of thiols and glutathione conjugates of depsipeptide FK228 (FR901228), a novel histone protein deacetylase inhibitor, in the blood. Rapid Commun Mass Spectrom. 17(8), 757-766 (2003).
39. Furumai R, Matsuyama A, Kobashi N et al. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62(17), 4916-4921 (2002).
40. Piekarz R, Bates S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Current Pharm. Des. 10(19), 2289-2298 (2004).
41. Byrd JC, Marcucci G, Parthun MR et al. A Phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105(3), 959-967 (2005).
42. Bates SE, Zhan Z, Steadman K et al. Laboratory correlates for a Phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br. J. Haematol. 148(2), 256-267 (2010).
43. Sandori V, Bakke S, Robey RW et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Cancer Res. 8(3), 718-728 (2002).
44. Celgene. Istodax: U.S. prescribing information (2012).
45. Berenson J YO, Mapes R et al. A Phase II study of a 1-hour infusion of romidepsin combined with bortezomib for multiple myeloma (MM) patients with relapsed or refractory disease. ASCO Meeting Abstracts. 27, e19508 (2009).
46. Woo S, Gardner ER, Chen X et al. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma. Clin. Cancer Res. 15(4), 1496-1503 (2009).
47. Piekarz RL, Robey R, Sandor V et al. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report. Blood 98(9), 2865-2868 (2001).
48. Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL et al. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood 117(22), 5827-5834 (2011).
49. Piekarz RL, Frye AR, Wright JJ et al. Cardiac studies in patients treated with depsipeptide, FK228, in a Phase II trial for T-cell lymphoma. Clin. Cancer Res. 12(12), 3762-3773 (2006).
50. Cabell C, Bates S, Piekarz R, et al. Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin. ASH Annual Meeting Abstracts 114(22), 3709 (2009).
51. Marshall JL, Rizvi N, Kauh J et al. A Phase I trial of depsipeptide (FR901228) in patients with advanced cancer. J. Exp. Ther Oncol. 2(6), 325-332 (2002).
52. Godfrey CJ, Cabell CH, Balser B, Wolfson J, Nichols J, Burris HA III. Exposure-QTc response analysis of class 1 selective histone deacetylase inhibitor romidepsin. ASH Annual Meeting Abstracts. 118(21), 2680 (2011).
53. Coiffier B, Pro B, Prince HM et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J. Clin. Oncol. 30(6), 631-636 (2012).
54. Coiffier B, Pro B, Prince M et al. Romidepsin Induces Durable Responses in Patients with Peripheral T-Cell Lymphoma: GPI-06-0002 Study Update. ASH Annual Meeting Abstracts. 120(21), 3641 (2012).
55. Horwitz S BC, Francine Foss, Miles Prince et al. Utility of 18fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a Phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma. Presented at: Pan Pacific Lymphoma Conference Hawaii (2011).
56. Dupuis J, Casasnovas R-O, Ghesquieres H et al. A Phase Ib trial of romidepsin in association with CHOP in patients with peripheral T-cell lymphoma (PTCL): the Ro-CHOP Study. ASH Annual Meeting Abstracts. 120(21), 1617 (2012).
57. Bishton MJ, Harrison SJ, Martin BP et al. Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia. Blood 117(13), 3658-3668 (2011).
58. Friedberg J, Mahadevan D, Jung J et al. Phase 2 trial of alisertib (MLN8237), an investigational, potent inhibitor of aurora A kinase (AAK), in patients (pts) with aggressive b-and T-cell non-hodgkin lymphoma (NHL). ASH Annual Meeting Abstracts. 118(21), 95 (2011).